The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Genome-wide association study of steady-state letrozole concentration in patients with breast cancer.
 
Daniel Louis Hertz
Research Funding - Disarm Therapeutics
(OPTIONAL) Uncompensated Relationships - PEPID; Saladax Biomedical
 
Julie Douglas
No Relationships to Disclose
 
Kelley M. Kidwell
No Relationships to Disclose
 
Christina L Gersch
No Relationships to Disclose
 
Zeruesenay Desta
No Relationships to Disclose
 
Anna Maria Storniolo
Employment - Boston Pharmaceuticals (I); Sophren Therapeutics (I)
Leadership - Boston Pharmaceuticals (I); Sophren Therapeutics (I)
Stock and Other Ownership Interests - Lilly (I); Merck; Merck (I)
Consulting or Advisory Role - Lilly
 
Vered Stearns
Consulting or Advisory Role - Iridium Therapeutics
Research Funding - Abbvie; Biocept; MedImmune; Novartis; Pfizer; Puma Biotechnology
Other Relationship - Immunomedics
 
Todd C. Skaar
No Relationships to Disclose
 
Daniel F. Hayes
Stock and Other Ownership Interests - InBiomotion; OncImmune
Consulting or Advisory Role - Agendia; Cellworks; Cepheid; CVS Caremark; Epic Sciences; Freenome; Salutogenic Innovations
Research Funding - AstraZeneca (Inst); Lilly (Inst); Menarini Silicon Biosystems (Inst); Merrimack (Inst); Pfizer (Inst); Puma Biotechnology (Inst)
Patents, Royalties, Other Intellectual Property - Circulating Tumor Cell Capturing Techniques and Devices. Patent No.: US 8,951,484 B2. Date of Patent: Feb. 10, 2015. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Diagnosis and Treatment of Breast Cancer. Patent No. US 8,790,878 B2. Date of Patent: Jul. 29, 2014. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Royalties from licensed technology.; Title: A method for predicting progression free and overall survival at each follow-up timepoint during therapy of metastatic breast cancer patients using circulating tumor cells. Patent no. 05725638.0-1223-US2005008602.
Travel, Accommodations, Expenses - Menarini Silicon Biosystems
Other Relationship - Menarini
(OPTIONAL) Uncompensated Relationships - UpToDate
 
Norah Lynn Henry
Research Funding - Abbvie (Inst); Innocrin Pharma (Inst); Pfizer (Inst)
 
James M. Rae
No Relationships to Disclose